Immediate Impact
51 standout
Citing Papers
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
2024 Standout
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2023 Standout
Works of John R. Crew being referenced
Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial
2005
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| John R. Crew | 280 | 161 | 246 | 173 | 23 | 713 | |
| G. McGreal | 322 | 103 | 81 | 59 | 32 | 718 | |
| Johan von Knorring | 231 | 340 | 212 | 40 | 40 | 724 | |
| Staffan Svenmarker | 350 | 98 | 312 | 61 | 29 | 633 | |
| Jeffrey T. Sugimoto | 217 | 232 | 212 | 56 | 26 | 594 | |
| Daniel Keenan | 479 | 144 | 433 | 22 | 29 | 761 | |
| Gaurav Gulati | 173 | 118 | 312 | 70 | 44 | 725 | |
| Roberto Zamparelli | 201 | 53 | 454 | 42 | 25 | 757 | |
| K. Johansson | 534 | 128 | 173 | 31 | 27 | 734 | |
| F L Grover | 358 | 111 | 368 | 17 | 16 | 693 | |
| Edgar C. Schick | 222 | 112 | 586 | 67 | 32 | 798 |
All Works
Loading papers...